
Opinion|Videos|May 15, 2025
Leveraging TAILORx Findings to Guide Testing and Treatment Decisions in Node-Negative Breast Cancer
Panelists discuss how the TAILORx trial data were transformative for estrogen receptor–positive breast cancer by establishing clearer thresholds for chemotherapy benefit, while raising important questions about whether younger patients with intermediate scores benefit from chemotherapy itself or from the ovarian suppression it causes.
Advertisement
TAILORx Trial Impact and Evolving Treatment Approaches
Main Discussion Topics:
- Interpretation of TAILORx data in treatment planning
- Chemotherapy regimen selection based on recurrence score
- Potential role of ovarian suppression vs chemotherapy in premenopausal patients
Key Points for Physicians:
- TAILORx transformed the interpretation of the 21-gene assay by providing clearer guidance for the intermediate-risk group.
- Higher recurrence scores may still warrant consideration of anthracycline-containing regimens.
- The NRG-BROO9 trial is investigating whether ovarian suppression rather than chemotherapy drives benefit in premenopausal patients.
Notable Insights:
- There is a broader trend toward reducing cytotoxic chemotherapy use across breast cancer subtypes.
- Despite advances in early-stage disease management, a significant proportion of breast cancer deaths occur in patients initially diagnosed with stage I-II disease.
Clinical Significance: TAILORx data have clarified treatment approaches for intermediate-risk scores, but questions remain about optimal chemotherapy regimens and whether ovarian suppression could replace chemotherapy in select premenopausal patients.
Advertisement
Related to this article

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

